---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-121180"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:14:14.232210+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioXcel stockholders approve reverse stock split authorization and elect directors

## Summary
- All five proposals passed at Dec 12 annual meeting; 44.68% of shares voted.
- Directors June Bray, Sandeep Laumas, David Mack elected as Class I directors.
- Ernst & Young ratified as independent auditor for FY2025.
- Advisory say-on-pay approved with ~78% of votes cast (excl. broker non-votes).
- Stockholders authorized reverse stock split of 1:2 to 1:20 to regain Nasdaq bid price compliance.

## SEC filing metadata
- accession: 0001104659-25-121180
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925121180/0001104659-25-121180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925121180/tm2533533d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-121180
- JSON: https://secwatch.observer/filing/0001104659-25-121180.json
- Plain text: https://secwatch.observer/filing/0001104659-25-121180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.